Spatiotemporal fractionation schemes for liver stereotactic body radiotherapy

被引:16
|
作者
Unkelbach, Jan [1 ]
Papp, David [2 ]
Gaddy, Melissa R. [2 ]
Andratschke, Nicolaus [1 ]
Hong, Theodore [3 ]
Guckenberger, Matthias [1 ]
机构
[1] Univ Hosp Zurich, Dept Radiat Oncol, Zurich, Switzerland
[2] North Carolina State Univ, Dept Math, Raleigh, NC USA
[3] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
基金
美国国家科学基金会;
关键词
Liver SBRT; Dose escalation; Fractionation; Treatment plan optimization; RADIATION-THERAPY; METASTASES; TRACKING;
D O I
10.1016/j.radonc.2017.09.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Dose prescription in stereotactic body radiotherapy (SBRT) for liver tumors is often limited by the mean liver dose. We explore the concept of spatiotemporal fractionation as an approach to facilitate further dose escalation in liver SBRT. Materials and methods: Spatiotemporal fractionation schemes aim at partial hypofractionation in the tumor along with near-uniform fractionation in normal tissues. This is achieved by delivering distinct dose distributions in different fractions, which are designed such that each fraction delivers a high single fraction dose to complementary parts of the tumor while creating a similar dose bath in the surrounding noninvolved liver. Thereby, higher biologically effective doses (BED) can be delivered to the tumor without increasing the mean BED in the liver. Planning of such treatments is performed by simultaneously optimizing multiple dose distributions based on their cumulative BED. We study this concept for five liver cancer patients with different tumor geometries. Results: Spatiotemporal fractionation presents a method of increasing the ratio of prescribed tumor BED to mean BED in the noninvolved liver by approximately 10-20%, compared to conventional SBRT using identical fractions. Conclusions: Spatiotemporal fractionation may reduce the risk of liver toxicity or facilitate dose escalation in liver SBRT in circumstances where the mean dose to the non-involved liver is the prescription-limiting factor. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:357 / 364
页数:8
相关论文
共 50 条
  • [31] Advances in Stereotactic Body Radiotherapy
    Guckenberger, Matthias
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S80 - S81
  • [32] Feasibility and tolerability of breath-hold in liver stereotactic body radiotherapy with surface guided radiotherapy
    Turna, Menekse
    Kucukmorkoc, Esra
    Rzazade, Rashad
    Canoglu, Mehmet Dogu
    Kucuk, Nadir
    Caglar, Hale Basak
    TECHNICAL INNOVATIONS & PATIENT SUPPORT IN RADIATION ONCOLOGY, 2023, 28
  • [33] A feasibility study of stereotactic radiosurgery/stereotactic body radiotherapy/stereotactic ablative radiotherapy practice using tomoedge in helical tomotherapy for lung, liver, and spine targets
    Sresty, N. V. N. Madhusudhana
    Raju, A. Krishnam
    Kumar, G. Deleep
    Rohit, S.
    Reddy, B. Nagarjuna
    Sahithya, V. C.
    Reddy, B. Devender
    Mohd, Yakub
    Rushdi, Tasneem
    Bajwa, Harjoth
    Aparna, S.
    JOURNAL OF MEDICAL PHYSICS, 2021, 46 (03) : 204 - 210
  • [34] Measuring the dose in bone for spine stereotactic body radiotherapy
    Shaw, Maddison
    Lye, Jessica
    Alves, Andrew
    Hanlon, Maximilian
    Lehmann, Joerg
    Supple, Jeremy
    Porumb, Claudiu
    Williams, Ivan
    Geso, Moshi
    Brown, Rhonda
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2021, 84 : 265 - 273
  • [35] Stereotactic body radiotherapy for distant metastases to the head and neck
    Mutsaers, Adam
    Abugharib, Ahmed
    Poon, Ian
    Loblaw, Joshua
    Bayley, Andrew
    Zhang, Liying
    Chin, Lee
    Galapin, Madette
    Erler, Darby
    Sahgal, Arjun
    Higgins, Kevin
    Enepekides, Danny
    Eskander, Antoine
    Karam, Irene
    SUPPORTIVE CARE IN CANCER, 2024, 32 (04)
  • [36] Stereotactic Ablative Body Radiotherapy for the Treatment of Spinal Oligometastases
    Chang, J. H.
    Gandhidasan, S.
    Finnigan, R.
    Whalley, D.
    Nair, R.
    Herschtal, A.
    Eade, T.
    Kneebone, A.
    Ruben, J.
    Foote, M.
    Siva, S.
    CLINICAL ONCOLOGY, 2017, 29 (07) : E119 - E125
  • [37] Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases
    Kao, Johnny
    Chen, Chien-Ting
    Tong, Charles C. L.
    Packer, Stuart H.
    Schwartz, Myron
    Chen, Shu-hsia
    Sung, Max W.
    TARGETED ONCOLOGY, 2014, 9 (02) : 145 - 153
  • [38] Dosimetric comparison of brachyablation and stereotactic ablative body radiotherapy in the treatment of liver metastasis
    Pennington, J. Daniel
    Park, Sang June
    Abgaryan, Narine
    Banerjee, Robyn
    Lee, Percy P.
    Loh, Christopher
    Lee, Edward
    Demanes, D. Jeffrey
    Kamrava, Mitchell
    BRACHYTHERAPY, 2015, 14 (04) : 537 - 542
  • [39] Stereotactic Body Radiotherapy and Ablative Therapies for Lung Cancer
    Abbas, Ghulam
    Danish, Adnan
    Krasna, Mark J.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 25 (03) : 553 - +
  • [40] Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic liver tumors
    Kirichenko, Alexander
    Gayou, Olivier
    Parda, David
    Kudithipudi, Vijay
    Tom, Kusum
    Khan, Akhtar
    Abrams, Peter
    Szramowski, Molly
    Oliva, Jose
    Monga, Dulabh
    Raj, Moses
    Ngoc Thai
    HPB, 2016, 18 (01) : 88 - 97